Koneksa

Our CEO & Co-Founder Chris Benko spoke on a panel at Biotech Showcase during #JPM25 week in SF. Investing In the TechBio Space: A Huge Impact on Therapeutic Development & a Shorter Time Frame to Revenue. TechBio companies generate revenue by providing services that enable and enhance drug and diagnostic development. They are not hindered by the long approval process and potential failures of the drug development that biotech companies face. Panelists: Celestine “Cee Cee” Schnugg -?Managing Partner,?Boom Capital Brent Vaughan?-?CEO,?Stealth TechBio Navjeewan Khosla?-?Partner,?Novo Holdings Chris Benko?-?CEO,?Koneksa Benjamin Vandendriessche?-?Chief Delivery Officer,?Digital Medicine Society (DiMe) Michael Sarshad?-?Managing Director, Commercial Advisory,?Syneos Health

We are excited to announce that our clinical study of Disease Progression in Parkinson's Disease (PD) KH007 (NCT06219629) achieved the last patient in (LPI). This is a multicenter, longitudinal, observational study to determine usability, validity, and reliability of digital assessments over a 12 month period amongst participants with PD. This study is conducted as a part of a curated collaboration with pharmaceutical partners Merck and Regeneron. We are proud to complete enrollment, which was concluded in less than 1 year from study start. Thank you to all the study participants for all of their efforts and high-quality data; we appreciate all the clinical sites, investigators and staff driving operational excellence. The results will deepen our understanding of PD and assess performance and compliance of digital data collection, which can pave the way for development of therapeutic interventions in early disease. Read more on our blog ?? https://lnkd.in/ePA3DUxU https://lnkd.in/ezz9ua8b https://lnkd.in/ecWduv38 #DHT #ParkinsonsDisease #clinicaltrials #drugdevelopment #evidencegeneration

Investing In the TechBio Space: A Huge Impact on Therapeutic Development & A Shorter Time Frame to Revenue ?? Biotech Showcase ?? San Francisco, CA ?? January 14, 2025 ?? 10:00 – 11:00 TechBio companies generate revenue by providing services that enable and enhance drug and diagnostic development. They are not hindered by the long approval process and potential failures of the drug development that biotech companies face. Moderator: Darren Coleman ? Panelists: Celestine “Cee Cee” Schnugg Brent Vaughan Navjeewan Khosla Chris Benko Jennifer Goldsack Find out what else is on the agenda >> https://lnkd.in/euTRssxz ? #BiotechShowcase #SanFrancisco Demy-Colton

Very proud of the work from the Koneksa team along with Olivier Harari (Regeneron), Aubrey Stoch (Merck) and Simon Davies (Takeda) describing our novel and collaborative approach to accelerate the development of new digital measures through Syndicated Studies! cc: Dave Hurry, Elena Izmailova, John Wagner, MD, PhD, ASCPT Journal Family

Koneksa, one of several companies that helps pharma and biotech study their treatments with wearables and smartphone apps, has been pitching drugmakers on?funding a study of GLP-1s for Parkinson's disease. When I heard the proposal at the company's offices, I was intrigued. A few notes: —Koneksa’s pitch to drug developers is that digital tools can provide a new window into how treatments impact patients and are potentially better at measuring disease progression than existing tools. Parkinson’s disease is a hotbed for exploring the potential of digital tools because?many argue the current measurement techniques are too coarse and infrequent to capture the impacts of drugs on the slow-moving disease. Customers include Merck, Regeneron, and Sanofi. —Koneksa's proposal was inspired by a successful randomized control trial?published earlier this year showing?that people with Parkinson’s on GLP-1 drug Lixisenatide saw no worsening of motor symptoms over a year, compared to those on placebo who did. But enthusiasm for the idea may be tamped down by a forthcoming readout from a Parkinson's study of another GLP-1 drug, Exenatide, that reportedly did not meet its primary endpoint. —Executives like Chris Benko and John Wagner, MD, PhD told me a one-year study of people with Parkinson's taking GLP-1s could help settle some outstanding questions about the potential of the drug class, including whether they have more impact on certain Parkinson's symptoms or subpopulations. That might be appealing to drugmakers hoping for a quick signal to help justify studying their drugs in Parkinson's — or maybe to support going out and acquiring a new asset. Read my whole article:

Excited to share our publication in Clinical and Translational Science, titled: "Syndication in Science: Curated Collaboration," in collaboration with researchers from Takeda, Regeneron and Merck. ???? “The syndication model combines the speed of single sponsor studies with the advantage of having multi-member expertise and risk sharing,” said John Wagner, MD, PhD, Chief Medical Officer, Koneksa. “By fostering a curated collaboration across key stakeholder groups, this syndication model enables real-time data insights, potentially faster study launches, and more efficient validation of digital measures, significantly accelerating the development of novel therapies for patients.” Link to the paper: https://lnkd.in/eVJdaHth Read our press release: https://lnkd.in/emjjt3cv #digitalbiomarkers #clinicaltrials #Parkinsons

STAT healthtech reporter Mario Aguilar spoke with our team about our data syndication efforts in Parkinson's disease, and spoke with our CEO Chris Benko and CMO John Wagner, MD, PhD. Tracking Parkinson’s: digital vs in-clinic measures Koneksa’s pitch to drug developers is that digital tools can provide a new window into how treatments impact patients and are potentially better at measuring disease progression than existing tools. For Koneksa and others, #Parkinson’s disease, a neurodegenerative condition with no approved disease-modifying treatments, has become a hotbed for exploring the potential of digital tools because as Benko puts it, there is a “measurement problem.” Benko, a former executive at Merck, said he hopes the data from Koneksa’s tools can inform drug developer decisions about whether to advance or abandon an experimental treatment. “Economically, what matters to a pharma is making the right choices about where to put their resources and where not to put resources,” he said. “And so my dearest hope is that we’re in a situation where we can show that a particular signal is worth acting on.” Gary Herman, senior vice president of early clinical development and experimental sciences at Regeneron, said that the company recognized the limitations of the common rating scale in detecting disease progression in Parkinson’s and had been considering its own research to see if it could find a way to get quicker feedback on its drug programs. Herman worked with Benko and Wagner at Merck, and said the opportunity to sign a contract and get instant access to Koneksa’s data was a “very appealing way for us to basically jump-start our efforts.” Read the article: https://lnkd.in/e757G6ZV

Thanks Contract Pharma for covering our recent CBO appointment of Eric Luthi. https://lnkd.in/eXSRT53U

eCOA Consortium Announces a New Article: Implementing Sensor-based Digital Health Technologies in Clinical Trials: Key Considerations from the eCOA Consortium C-Path’s eCOA Consortium is pleased to announce that Implementing Sensor-based Digital Health Technologies in Clinical Trials: Key Considerations from the eCOA Consortium has been published in the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Journal Clinical and Translational Science. The article provides an in-depth assessment of the scientific considerations around the use of sensor-based digital health technologies in clinical trials, all set in the context of supporting trial participant compliance with these technologies. Detailing key topics from clinical considerations to data sharing, the paper represents the collection of eCOA Consortium member experience coupled with peer-reviewed literature and relevant regulatory recommendations. Access here:?https://lnkd.in/eZyDKYTW #eCOA #CPath #DHT #DrugDevelopment

We’re thrilled to welcome Eric Luthi as Chief Business Officer. In this newly created role, Mr. Luthi brings over 25 years of experience in life sciences and will lead corporate and business development initiatives at Koneksa. “We’re thrilled to welcome Eric to lead our business development team,” said Chris Benko, CEO and Co-Founder of Koneksa. “With his extensive industry expertise and proven success in driving growth and strategy, Eric will play a pivotal role in advancing our strategic initiatives and forming essential partnerships with leading healthcare organizations. His leadership will be invaluable as we empower biopharma companies to utilize digital biomarkers to accelerate clinical trials and unlock critical data insights.” Read the release: https://lnkd.in/eiTKrj2z